Comparative Pharmacology
Head-to-head clinical analysis: ADVIL versus DYLOJECT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL versus DYLOJECT.
ADVIL vs DYLOJECT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby reducing pain, fever, and inflammation.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day (OTC). For prescription: 400-800 mg orally 3-4 times daily; maximum 3200 mg/day.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
None Documented
None Documented
2-4 hours (terminal elimination half-life in adults; prolonged in overdose or renal impairment: up to 8-12 hours)
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
Renal: ~95% (hepatic metabolites and conjugates, <1% unchanged); biliary/fecal: ~5%
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Category C
Category C
NSAID
NSAID